# Uncomplicated Plasmodium Falciparum Malaria FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/uncomplicated-plasmodium-falciparum-malaria

> 2 upcoming FDA catalysts in uncomplicated Plasmodium Falciparum Malaria: cipargamin (NVS) on Feb to May 2027 (topline data readout); cipargamin (NVS) on February 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 27, 2025 | [KLU156 primary completion](https://sec-api.dev/pdufa/klu156) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT05842954 (Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842954)) |
| June 2026 | [INE963 primary completion](https://sec-api.dev/pdufa/ine963) | NVS | Uncomplicated Plasmodium Falciparum Malaria | delayed | "NCT05750628 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05750628)) |
| June 17, 2026 | [INE963 primary completion](https://sec-api.dev/pdufa/ine963) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT07811882 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811882)) |
| November 4, 2026 | [KLU156 topline data readout](https://sec-api.dev/pdufa/klu156) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT05842954 (Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842954?tab=results)) |
| Feb to May 2027 | [Cipargamin topline data readout](https://sec-api.dev/pdufa/cipargamin) | NVS | Uncomplicated Plasmodium Falciparum Malaria | scheduled | "NCT07811908 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811908)) |
| February 2027 | [Cipargamin primary completion](https://sec-api.dev/pdufa/cipargamin) | NVS | Uncomplicated Plasmodium Falciparum Malaria | scheduled | "NCT07811908 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811908)) |

## Drugs

- [KLU156](https://sec-api.dev/pdufa/klu156) (NVS)
- [INE963](https://sec-api.dev/pdufa/ine963) (NVS)
- [Cipargamin](https://sec-api.dev/pdufa/cipargamin) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/uncomplicated-plasmodium-falciparum-malaria.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Uncomplicated Plasmodium Falciparum Malaria FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/uncomplicated-plasmodium-falciparum-malaria

```bibtex
@misc{secapidev_indications_uncomplicated_plasmodium_falciparum_malaria_20261116,
  title        = {Uncomplicated Plasmodium Falciparum Malaria FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/uncomplicated-plasmodium-falciparum-malaria}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_uncomplicated_plasmodium_falciparum_malaria_20261116","title":"Uncomplicated Plasmodium Falciparum Malaria FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/uncomplicated-plasmodium-falciparum-malaria","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
